Precision Prostate Consulting, LLC announces its rebrand to DeepView Imaging, reflecting the company's mission to provide patients with direct, on-demand access to AI-powered prostate MRI analysis. Through its HIPAA-compliant platform, patients can upload their MRI and receive comprehensive diagnostic reports in 10–30 minutes using ProstatID™—North America's first FDA-cleared AI software for prostate cancer screening, detection, and diagnosis.

KENNEBUNK, Maine, April 1, 2026 /PRNewswire-PRWeb/ -- Precision Prostate Consulting, LLC (PPC), a leader in AI-powered prostate MRI analysis, today announced its official rebrand to DeepView Imaging. The new name reflects the company's direct-access platform and its expanding mission to democratize access to fast, AI-powered second opinions for prostate MRI—delivering actionable imaging insights when patients need them most.

Since its founding, the company has enabled patients to take a more active role in their prostate health by providing access to advanced imaging analysis without requiring referrals or long wait times. Through its HIPAA-compliant, patient-friendly platform, patients can upload their prostate MRI and receive a comprehensive AI-driven report in 10–30 minutes—one they can confidently discuss with their care team.

"This rebrand reflects both the technology at the core of our platform and a fundamentally different way for patients to access advanced imaging analysis," said Jamie Richgels, Managing Partner. "DeepView Imaging gives patients direct, on-demand access to AI-powered prostate MRI insights—removing friction from the process and helping them move forward with greater clarity and confidence."

DeepView Imaging offers patients direct access to ProstatID™, developed by Bot Image AI—North America's first FDA-cleared AI software for prostate cancer screening, detection (CADe), and diagnosis (CADx). ProstatID is deployed in hospitals and imaging centers across the United States and has received CE Mark (EU) and UKCA certification (UK), supporting broader clinical adoption in international markets.

Through the DeepView Imaging platform, patients receive detailed diagnostic reports along with enhanced DICOM images featuring color overlays that highlight regions suspicious for clinically significant cancer. This additional layer of analysis helps patients and their physicians better understand imaging results and supports more informed clinical decisions.

"Interpreting prostate MRI is highly nuanced, and even experienced radiologists can have variability in their assessments," said Randall W. Jones, PhD, Managing Partner. "Providing an additional layer of objective, AI-driven analysis can help surface clinically significant findings and give both patients and physicians greater confidence in how to proceed."

In addition to one-time analyses, DeepView Imaging offers reduced-cost follow-up scans for ongoing monitoring or active surveillance, as well as educational resources to help patients better understand prostate cancer, imaging findings, and potential treatment pathways. The company also plans to introduce connections to board-certified urologists for patients seeking additional clinical guidance or second opinions.

The rebrand includes a new visual identity and an updated digital experience, with a new website available at https://deepviewimaging.com. While the company's name has changed, its commitment to patient-centered care, rapid turnaround times, and clinically validated AI technology remains the same.

About DeepView Imaging

DeepView Imaging is a healthcare technology company providing patients and physicians with advanced prostate MRI analysis powered by ProstatID™. Through its direct-access platform, the company delivers fast, objective, and clinically validated insights that improve diagnostic clarity, confidence, and decision-making. For more information, visit https://deepviewimaging.com.

About ProstatID™

ProstatID™, developed by Bot Image AI, is North America's first FDA-cleared AI software for prostate cancer screening, detection (CADe), and diagnosis (CADx). The platform is trained on thousands of biopsy-confirmed MRI scans and has demonstrated strong performance, with an AUROC of 0.936. ProstatID is also CE-Marked (EU) and UKCA-Certified (UK). For more information, visit https://botimageai.com/prostatid.

Media Contact

Jamie Richgels, DeepView Imaging, 1 (202) 838-7563, info@deepviewimaging.com, https://www.deepviewimaging.com/

View original content:https://www.prweb.com/releases/precision-prostate-consulting-announces-rebrand-to-deepview-imaging-reflecting-expanded-mission-in-ai-powered-prostate-cancer-detection-302731806.html

SOURCE DeepView Imaging